Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.75 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.75 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.71 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.68 |
| ▸ | MAOA | P21397 | 2/20 | 0.68 |
| ▸ | MAOB | P27338 | 2/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.68 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.68 |
| ▸ | CA1 | P00915 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373668 | 1.00 | MEN1 (1.00) | MEN1KMT2AHPGDTP53ALOX15 | |
| SCHEMBL6832163 | 0.89 | HPGD (0.80) | MEN1KMT2AHPGDTP53ALOX15 | |
| SCHEMBL30143812 | 0.88 | HPGD (0.78) | MEN1KMT2AHPGDTP53ALOX15 | |
| SCHEMBL1058712 | 0.88 | HPGD (0.78) | MEN1KMT2AHPGDTP53ALOX15 | |
| SCHEMBL312255 | 0.86 | AKR1C3 (1.00) | MEN1KMT2AHPGDTP53ALOX15 | |
| SCHEMBL15676209 | 0.85 | MEN1 (0.74) | MEN1KMT2AHPGDTP53ALOX15 | |
| SCHEMBL10810027 | 0.85 | HPGD (0.74) | MEN1KMT2AHPGDTP53ALOX15 | |
| SCHEMBL7806215 | 0.84 | KMT2A (0.72) | MEN1KMT2AHPGDTP53ALOX15 | |
| SCHEMBL4650047 | 0.83 | HPGD (1.00) | MEN1KMT2AHPGDTP53ALOX15 | |
| SCHEMBL7127255 | 0.82 | KDM4E (0.73) | MEN1KMT2AHPGDTP53ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 518 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282871-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | TIANJIN LIPOGEN TECH CO LTD (CN) | 2025-09-11 | — | — | US | claimed |
| US-20250195452-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | IATERION, INC. | 2025-06-19 | — | — | US | claimed |
| US-20240285755-A1 | Adjuvants | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-08-29 | — | — | US | claimed |
| US-20240277751-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-22 | — | — | US | claimed |
| EP-4346894-A1 | ADJUVANTS | GlaxoSmithKline Biologicals S.A. (BE) | 2024-04-10 | — | — | EP | claimed |
| EP-4342492-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | Tianjin Lipogen Technology Co., Ltd (CN) | 2024-03-27 | — | — | EP | claimed |
| CN-117396222-A | Pharmaceutical combination and use thereof | 天津立博美华基因科技有限责任公司 | 2024-01-12 | — | — | CN | claimed |
| EP-4228657-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | The Regents Of The University Of Michigan (US) | 2023-08-23 | — | — | EP | claimed |
| CN-116390764-A | Crystalline polymorphic forms of STING agonist bound to metal ions capable of modulating immune responses | 密歇根大学董事会 | 2023-07-04 | — | — | CN | claimed |
| US-20220387470-A1 | METHODS OF MODULATING IMMUNE ACTIVITY | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2022-12-08 | — | — | US | claimed |
| WO-2013006743-A2 | PERSONAL CARE COMPOSITIONS WITH IMPROVED SOLUBILITY OF A SOLID COSMETIC ACTIVE | THE PROCTER & GAMBLE COMPANY (US) | 2013-01-10 | — | — | WO | claimed |
| US-20130011347-A1 | Personal Care Compositions With Improved Solubility of a Solid Cosmetic Active | THE PROCTER & GAMBLE COMPANY | 2013-01-10 | — | — | US | claimed |
| WO-2007084614-A2 | HAIR GROWTH FORMULA | SAKURA PROPERTIES, LLC (US) | 2007-07-26 | — | — | WO | claimed |
| WO-2007084721-A2 | SKIN PROTECTION AND MOISTURIZING COMPOSITIONS AND METHODS | SAKURA PROPERTIES, LLC (US) | 2007-07-26 | — | — | WO | claimed |
| US-20060210515-A1 | HAIR GROWTH FORMULA | SAKURA PROPERTIES, LLC | 2006-09-21 | — | — | US | claimed |
| US-20060210524-A1 | SKIN CARE COMPOSITION | SAKURA PROPERTIES, LLC | 2006-09-21 | — | — | US | claimed |
| US-6872771-B1 | Tire with rubber containing flavone | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2005-03-29 | — | — | US | claimed |
| JP-2003504327-A | — | — | 2003-02-04 | — | — | JP | claimed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | claimed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130011347-A1 | Personal Care Compositions With Improved Solubility of a Solid Cosmetic Active | ASS1, C1R, CUTA | MEN1 2813/4885KMT2A 3411/4885HPGD 1692/4885 |
| US-20220387470-A1 | METHODS OF MODULATING IMMUNE ACTIVITY | STING1, IRF3, CGAS | MEN1 4349/4885KMT2A 4415/4885HPGD 2044/4885 |
| US-20250195452-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | ESR2, ESR1, ESRRB | MEN1 2127/4885KMT2A 4051/4885HPGD 922/4885 |
| US-20240285755-A1 | Adjuvants | STING1, TLR3, TLR9 | MEN1 3362/4885KMT2A 2136/4885HPGD 3394/4885 |
| US-20060210524-A1 | SKIN CARE COMPOSITION | CUTA, PLOD3, KRT18 | MEN1 3918/4885KMT2A 1593/4885HPGD 2845/4885 |
| US-20240277751-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | STING1, CGAS, IRF3 | MEN1 2384/4885KMT2A 4129/4885HPGD 2823/4885 |
| US-20060210515-A1 | HAIR GROWTH FORMULA | HGF, HDGF, HGFAC | MEN1 1159/4885KMT2A 3328/4885HPGD 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.